Literature DB >> 15799828

Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.

Vemparala Subbarayan1, Xiao-Chun Xu, Jeri Kim, Peiying Yang, Ashraful Hoque, Anita L Sabichi, Norma Llansa, Gabriella Mendoza, Christopher J Logothetis, Robert A Newman, Scott M Lippman, David G Menter.   

Abstract

15-Lipoxygenase-2 (15-LOX-2) synthesizes 15-S-hydroxyeicosatetraenoic acid (15-S-HETE), an endogenous ligand for the nuclear receptor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Several studies have described an inverse relationship between 15-LOX-2 and PPAR-gamma expression in normal versus tumor samples. To systematically determine if this is a ubiquitous phenomenon, we used a variety of epithelial and nonepithelial cells and some tissues to further evaluate the extent of this inverse relationship. The levels of mRNA or protein were measured by reverse transcriptase polymerase chain reaction or Western gray level intensity, whereas distribution was determined by in situ hybridization or immunofluorescence. 15-S-HETE was measured by liquid chromatography/tandem mass spectrometry. Normal epithelial cells/samples generally expressed high levels of 15-LOX-2 along with the enzyme product 15-S-HETE, but both levels were reduced in cancer cells/samples. In contrast, most cancer cells expressed high levels of PPAR-gamma mRNA and protein, which were absent from normal epithelial cells. Overall, the inverse relationship between these two genes was primarily restricted to epithelial samples. Forced expression of PPAR-gamma reduced 15-LOX-2 protein levels in normal cells, whereas forced expression of 15-LOX-2 in tumor cells suppressed PPAR-gamma protein levels. These results suggest that feedback mechanisms may contribute to the loss of 15-LOX-2 pathway components, which coincide with an increase in PPAR-gamma in many epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799828      PMCID: PMC1501140          DOI: 10.1593/neo.04457

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  73 in total

Review 1.  Roles of PPARs in health and disease.

Authors:  S Kersten; B Desvergne; W Wahli
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

Review 2.  Troglitazone and related compounds: therapeutic potential beyond diabetes.

Authors:  T Fujiwara; H Horikoshi
Journal:  Life Sci       Date:  2000-10-06       Impact factor: 5.037

Review 3.  Basic mechanisms of secretion: sorting into the regulated secretory pathway.

Authors:  M Blázquez; K I Shennan
Journal:  Biochem Cell Biol       Date:  2000       Impact factor: 3.626

4.  Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2.

Authors:  M Jisaka; R B Kim; W E Boeglin; A R Brash
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

5.  Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.

Authors:  Ken Yajima; Hiroshi Hirose; Haruhisa Fujita; Yoshiko Seto; Hiroshi Fujita; Kaname Ukeda; Kiichi Miyashita; Toshihide Kawai; Yukihiro Yamamoto; Takeo Ogawa; Taketo Yamada; Takao Saruta
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-05       Impact factor: 4.310

6.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

Authors:  D S Straus; G Pascual; M Li; J S Welch; M Ricote; C H Hsiang; L L Sengchanthalangsy; G Ghosh; C K Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene.

Authors:  P Shankaranarayanan; P Chaitidis; H Kühn; S Nigam
Journal:  J Biol Chem       Date:  2001-08-16       Impact factor: 5.157

8.  Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.

Authors:  Vemparala Subbarayan; Anita L Sabichi; Jeri Kim; Norma Llansa; Christopher J Logothetis; Scott M Lippman; David G Menter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-11       Impact factor: 4.254

9.  Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.

Authors:  G S Jack; A R Brash; S J Olson; S Manning; C S Coffey; J A Smith; S B Shappell
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

Review 10.  PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.

Authors:  G J Murphy; J C Holder
Journal:  Trends Pharmacol Sci       Date:  2000-12       Impact factor: 14.819

View more
  20 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.

Authors:  Imran Ahmad; Ernest Mui; Laura Galbraith; Rachana Patel; Ee Hong Tan; Mark Salji; Alistair G Rust; Peter Repiscak; Ann Hedley; Elke Markert; Carolyn Loveridge; Louise van der Weyden; Joanne Edwards; Owen J Sansom; David J Adams; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

3.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

4.  Glutamine activates peroxisome proliferator-activated receptor-γ in intestinal epithelial cells via 15-S-HETE and 13-OXO-ODE: a novel mechanism.

Authors:  Kechen Ban; Julie M Sprunt; Stephanie Martin; Peiying Yang; Rosemary A Kozar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-07-07       Impact factor: 4.052

5.  Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation.

Authors:  S Fogli; F Stefanelli; L Picchianti; M Del Re; V Mey; C Bardelli; R Danesi; M C Breschi
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Absence of glutathione peroxidase 4 affects tumor angiogenesis through increased 12/15-lipoxygenase activity.

Authors:  Manuela Schneider; Markus Wortmann; Pankaj Kumar Mandal; Warangkana Arpornchayanon; Katharina Jannasch; Frauke Alves; Sebastian Strieth; Marcus Conrad; Heike Beck
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

Review 7.  Genomics of prostate cancer: is there anything to "translate"?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

8.  Arachidonate 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid contribute to stromal aging-induced progression of pancreatic cancer.

Authors:  Ehab H Sarsour; Jyung Mean Son; Amanda L Kalen; Wusheng Xiao; Juan Du; Matthew S Alexander; Brianne R O'Leary; Joseph J Cullen; Prabhat C Goswami
Journal:  J Biol Chem       Date:  2020-04-07       Impact factor: 5.157

9.  Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.

Authors:  Raju C Reddy; Anjaiah Srirangam; Kaunteya Reddy; Jun Chen; Srinivasareddy Gangireddy; Gregory P Kalemkerian; Theodore J Standiford; Venkateshwar G Keshamouni
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

10.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

Authors:  M J Schiewer; L M Morey; C J Burd; Y Liu; D E Merry; S-M Ho; K E Knudsen
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.